All In Biotech

Drug Trial Radar · NCT02675465

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease

Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

29

Actual

Start

Apr 2016

Primary completion

Aug 22, 2024

Study completion Aug 22, 2024

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.

Conditions

  • Pompe Disease

Interventions

  • ATB200Drug

  • AT2221Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events (AEs) Leading to Discontinuation of Study DrugTime frame: Stage 3 (2 year treatment) and Stage 4 (Extension) combined, (mean = 71 months on treatment)
  2. Plasma Human Acid α-glucosidase (GAA) Activity Levels as Measured by Maximum Observed Plasma Concentration (Cmax).Time frame: 18 Weeks
  3. Plasma GAA Activity Levels as Measured by Time to Reach the Maximum Observed Plasma Concentration (Tmax).Time frame: 18 Weeks
  4. Plasma GAA Activity Levels as Measured by Area Under the Plasma Drug Concentration-time Curve (AUC).Time frame: 18 Weeks

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Centre

    Phoenix, Arizona

  • University of California Irvine

    Orange, California

  • University of Florida

    Gainesville, Florida

  • Emory University Division of Medical Genetics

    Decatur, Georgia

  • Infusion Associates

    Grand Rapids, Michigan

  • Great Falls Clinic, LLP

    Great Falls, Montana

  • Rutgers New Jersey Medical School

    Newark, New Jersey

  • Duke University Medical Center

    Durham, North Carolina

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Abramson Cancer Center Chester County Hospital

    West Chester, Pennsylvania

  • Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

    Fairfax, Virginia

  • Womens & Childrens Hospital, Adelaide

    North Adelaide, South Australia, Australia

  • University Children's Hospital Department of Neuropediatrics and Inborn Metabolic Disorders, St. Josefs-Hospital

    Bochum, Germany

  • Friedrich-Baur-Institure, Dep of Neurology - University Munich

    Munich, Germany

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • School of Medicine, University of Auckland

    Auckland, New Zealand

  • University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Medical Center

    Birmingham, United Kingdom

  • Salford Royal NHS Foundation Trust

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.